权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Near infrared intraoperative molecular imaging of lung adenocarcinoma

肺腺癌近红外术中分子影像

基本信息

批准号：
9030040
负责人：
PHILIP Stewart LOW
金额：
$ 69.83万
依托单位：
UNIVERSITY OF PENNSYLVANIA
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-03-01 至 2021-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9030040
关键词：
Accounting Address Applications Grants Biocompatible Biology Biomedical Research Body cavities Cancer Detection Cancer Patient Canis familiaris Caring Cells Characteristics Chemistry Cholecystokinin B Receptor Clinical Clinical Data Clinical Trials Collaborations Companions Contrast Media Curative Surgery Data Detection Development Diagnostic Neoplasm Staging Disease Drainage procedure Dyes EGF gene Ensure Epidermal Growth Factor Receptor Excision Faculty Feasibility Studies Folic Acid Follow-Up Studies Genetic Heterogeneity Goals Grant High Prevalence Human Image Image-Guided Surgery Imagery Industry Joints Laboratories Left Lung Lung Adenocarcinoma Lung Neoplasms Lymphatic Malignant - descriptor Malignant Neoplasms Malignant neoplasm of lung Maps Micrometastasis Modeling Molecular Mus Near-infrared optical imaging Neoplasm Metastasis Nodule Operating Rooms Operative Surgical Procedures Optics Paper Patient Care Patient-Focused Outcomes Patients Peer Review Grants Pennsylvania Phase Phenotype Polyps Preparation Primary Neoplasm Production Publishing Pulmonary Pathology Recurrence Relapse Research Project Grants Resectable Resected Residual Tumors Residual state Solid Neoplasm Specificity Staging Surgeon Survival Rate Technology Testing Thoracic Surgical Procedures Time Tissues Toxicology Tracer Translating Translations United States Universities Veterinary Medicine Work base bioimaging body cavity cancer cell cancer imaging cancer surgery capsule clinical application clinically relevant collaborative environment drug development experience image guided imaging agent improved innovation innovative technologies intraoperative imaging lymph nodes molecular imaging neoplastic cell new technology operation particle pre-clinical prevent public health relevance standard of care tumor tumor heterogeneity

项目摘要

DESCRIPTION (provided by applicant): The primary goal of this Biomedical Research Grant is to translate imaging agents for intraoperative cancer detection and image-guided surgery. Half of all cancer patients undergo surgery to remove their tumor. The single most important predictor of patient survival is a complete surgical resection of the primary tumor, draining lymph nodes, and metastatic lesions. However, up to 40% of surgical patients leave the operating room with malignant cells remaining after resection. Thus, there are urgent unmet needs to develop new and innovative technologies that can assist the surgeon in ensuring complete tumor resection by delineating tumor margins, and identifying micrometastases and draining lymph nodes. We propose a new technology to image patients at the conclusion of the standard-of-care cancer operation in order to discover residual local disease before completing the surgery. While the proposed technologies are broadly applicable to solid tumors, this project is specifically committed to improving detection of lung adenocarcinomas, one of the most aggressive human malignancies. To accomplish this goal, we have assembled a collaborative team at University of Pennsylvania and Purdue University with synergistic expertise in clinical trials, folate biology, chemistry, lung pathology, thoracic surgery and veterinary medicine. The proposed work will optimize three distinct types of contrast agents for a translational intraoperative imaging clinical trial. The first contrast agent uses folate to target a conjugated NIR dye specifically to malignant tissue. The folate-NIR agent will be evaluated in a first-in- human clinical trial of lung adenocarcinoma patients in order to determine if there is a benefit of intraoperative imaging to standard-of-care surgical approaches. The second contrast agent uses the same targeting approach to deliver a near-infrared dye for EGFR and CCK2R to cancer cells and allow better imaging of diseased cells more deeply buried in the tissues. This will allow for precise tumor localization and more accurate resection of cancers without violating the tumor capsule or seeding the body cavity.